The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Open accessAbstract
BACKGROUND Mosunetuzumab is a CD20 × CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and active in patients with relapsed or refractory B-cell lymphoma. We, therefore, aimed to evaluate the safety and anti-tumour activity of fixed-duration mosunetuzumab in patients with relapsed or refractory follicular lymphoma who had received two or more previous therapies. METHODS We conducted a single-arm, multicentre, phase 2 study at 49 centres in seven countries (Australia, Canada, Germany, South Korea, Spain, UK, and USA). All patients were aged 18 years or older with histologically confirmed follicular lymphoma (grade 1-3a) and an Eastern Cooperative Oncology Group performance status of 0-1. Patients had disease that was relapsed or refractory to two or more previous lines of treatment, including an anti-CD20 therapy and an alkylating agent. Intravenous mosunetuzumab was administered in 21-day cycles with cycle 1 step-up dosing: 1 mg on cycle 1 day 1, 2 mg on cycle 1 day 8, 60 mg on cycle 1 day 15 and cycle 2 day 1, and 30 mg on day 1 of cycle 3 and onwards. Patients with a complete response by investigator assessment using the International Harmonisation Project criteria completed treatment after cycle 8, whereas patients with a partial response or stable disease continued treatment for up to 17 cycles. The primary endpoint was independent review committee-assessed complete response rate (as best response) in all enrolled patients; the primary efficacy analysis compared the observed IRC-assessed complete response rate with a 14% historical control complete response rate in a similar patient population receiving the pan class I PI3K inhibitor copanlisib. Safety was assessed in all enrolled patients. This study is registered with ClinicalTrials.gov, number NCT02500407, and is ongoing. FINDINGS Between May 2, 2019, and Sept 25, 2020, we enrolled 90 patients. As of the data cutoff date (Aug 27, 2021), the median follow-up was 18·3 months (IQR 13·8-23·3). According to independent review committee assessment, a complete response was recorded in 54 patients (60·0% [95% CI 49·1-70·2]). The observed complete response rate was significantly higher than the historical control complete response rate with copanlisib of 14% (p<0·0001), thereby meeting the primary study endpoint. Cytokine release syndrome was the most common adverse event (40 [44%] of 90 patients) and was predominantly grade 1 (23 [26%] of 90) and grade 2 (15 [17%]), and primarily confined to cycle 1. The most common grade 3-4 adverse events were neutropenia or neutrophil count decreased (24 [27%] of 90 patients), hypophosphataemia (15 [17%]), hyperglycaemia (seven [8%]), and anaemia (seven [8%]). Serious adverse events occurred in 42 (47%) of 90 patients. No treatment-related grade 5 (ie, fatal) adverse event occurred. INTERPRETATION Fixed-duration mosunetuzumab has a favourable safety profile and induces high rates of complete remissions, allowing potential administration as an outpatient regimen, in patients with relapsed or refractory follicular lymphoma and two or more previous therapies. FUNDING F Hoffmann-La Roche and Genentech.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationObinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 604
Self-citationTisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
Self-citationHutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A., Salles, G., Martínez-Lopez, J., Crump, M., Thomas, D. N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03175 · Cited by 437
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4648 · Cited by 395
Self-citation
Research works printed but not linked: 2
- Bachy, 2021, Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival, Blood Adv, 5, 1729, 10.1182/bloodadvances.2020003797 · doi:10.1182/bloodadvances.2020003797
- van de Wiel, 2021, Manufacturing commercial axicabtagene ciloleucel for European patients: a 2-year retrospective analysis, HemaSphere, 5, 691
Cited by
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00166-2 · Cited by 171
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood · doi:10.1182/blood.2024025454 · Cited by 94
Self-citationLim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.02.010 · Cited by 62
Metadata
- Authors
- Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C.-C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 23
- Issue
- 8
- Pages
- 1055-1065
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4284987950
- Cited by
- 461
- References
- 23
- FWCI
- 53.27
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Genentech
- F. Hoffmann-La Roche
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00335-7
- The paper
- Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C. Y., Wei, M. C., Yin, S., Li, C.-C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00335-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.